Clinical Trial Update: A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating povorcitinib for prurigo nodularis is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Povorcitinib (povorcitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Prurigo Nodularis | Phase 3 | Status: ACTIVE_NOT_RECRUITING